Growing Medicine: How Scientists Are Making Psilocybin Production Better

In a lab at Miami University, scientists have just broken their own record for making psilocybin—the active compound in "magic mushrooms." They did this using genetically modified bacteria. This breakthrough could change how we make medicines for treating depression, addiction, and anxiety. This achievement could help make psychedelic therapy more affordable and available to millions of people with mental health conditions that don't respond well to current treatments.

From Ancient Medicine to Modern Breakthrough

Humans have used mushrooms containing psilocybin for thousands of years. Indigenous cultures across the Americas have long used these fungi in healing and spiritual practices. Now, modern science is catching up to this ancient wisdom. Clinical trials show promising results for conditions ranging from depression to end-of-life anxiety. But there's a problem: making pharmaceutical-grade psilocybin is expensive and complicated. Until recently, researchers and drug companies had two main options: extract it from mushrooms (which is inconsistent and hard to scale up) or make it chemically (which involves complex, costly processes).A third approach—using genetically engineered microorganisms—has emerged as a promising option. And now, researchers at Miami University have pushed this method to new heights.

Breaking Records with Bacteria

The research team, led by Madeleine Keller and Madeline McKinney, has achieved the highest production of psilocybin ever reported from a recombinant host: 1.46 grams per liter. This beats their previous record of 1.16 grams per liter. "We're basically teaching bacteria to make psilocybin for us," explains Dr. J. Andrew Jones, one of the study's authors. "By optimizing which genes we use and how they're expressed, we've created tiny cellular factories that produce psilocybin more efficiently than ever before. "The team's approach involved examining genes from four different mushroom species that naturally produce psilocybin: Psilocybe cubensis (the most common "magic mushroom"), Psilocybe cyanescens, Panaeolus cyanescens, and Gymnopilus dilepis. By testing different combinations of genes from these species, they identified which ones worked best together to maximize psilocybin production.

How Bacteria Make Magic

To understand this achievement, it helps to know how psilocybin is made in nature. Mushrooms produce psilocybin through a series of chemical reactions, each helped by specific enzymes (specialized proteins that speed up chemical reactions).The researchers focused on three key enzymes involved in this process:

1. PsiD (a decarboxylase): This enzyme removes a carboxyl group from the starting compound.
2. PsiK (a kinase): This enzyme adds a phosphate group.
3. PsiM (a methyltransferase): This enzyme adds methyl groups in sequence.

The team discovered that while the PsiD and PsiK enzymes from Psilocybe cubensis performed best, the PsiM enzyme showed interesting variations depending on which mushroom species it came from. The most productive strain used the PsiM enzyme from Gymnopilus dilepis, a lesser-known mushroom species. "Different mushroom species produce these compounds in different ratios," notes Keller. "By mixing and matching genes from different species, we can control not just how much psilocybin is produced, but also the balance of related compounds."

Why This Matters for Mental Health

The FDA has granted "breakthrough therapy" status to psilocybin-based treatments for several mental health conditions. This signals the agency's recognition of psilocybin's therapeutic potential and desire to speed its development. Clinical trials have shown remarkable results. In studies of treatment-resistant depression, a single dose of psilocybin, combined with psychological support, has produced significant reductions in depression symptoms that last for weeks or months. Similar promising results have been seen for anxiety, addiction, and end-of-life distress. But if psilocybin therapy is to become widely available, production methods need to be scaled up dramatically while maintaining quality and reducing costs. This is where biosynthesis comes in. "Chemical synthesis of psilocybin involves multiple steps, harsh chemicals, and extensive purification," explains Dr. Elle Hellwarth, another researcher on the team. "Biosynthesis is potentially more sustainable, scalable, and cost-effective. The bacteria do most of the complex chemistry for us."

From Lab to Therapy Room

Currently, about one in five U.S. adults lives with some form of mental illness. Standard treatments like antidepressants and therapy help many people, but a significant percentage don't respond well. For these individuals, psychedelic therapy offers a new avenue of hope. The biosynthesis breakthrough could help address several challenges facing psychedelic medicine:

1. Cost: By making production more efficient, biosynthesis could reduce the cost of psilocybin therapy, which currently can run thousands of dollars per treatment session.
2. Consistency: Bacterial production creates a more consistent product than extraction from mushrooms, ensuring patients receive precise, standardized doses.
3. Scalability: As demand for psychedelic therapy grows, biosynthesis methods can be scaled up more easily than other production methods.
4. Sustainability: Biosynthesis typically has a smaller environmental footprint than chemical synthesis, which often involves petroleum-derived reagents and generates hazardous waste.

"We're not just interested in making more psilocybin," says McKinney. "We want to make it in a way that's sustainable and accessible. If these treatments are going to help address the mental health crisis, they need to be available to everyone who needs them, not just those who can afford boutique therapies."

Beyond Psilocybin: The Wider Potential

The research has implications beyond just psilocybin production. The team also demonstrated the ability to produce related compounds like baeocystin, which may have their own therapeutic properties. "Different mushroom species produce different ratios of these compounds," explains Dr. Abhishek Sen, a co-author of the study. "By understanding and controlling the enzymes involved, we can potentially create customized formulations with specific effects. "The team found that the PsiM enzyme from Psilocybe cyanescens led to higher production of baeocystin, while providing evidence that PsiM can indeed catalyze the formation of aeruginascin, though at low levels. This ability to produce not just psilocybin but related compounds could enable researchers to study the "entourage effect"—the idea that multiple compounds working together might produce different or better therapeutic effects than isolated compounds.

Challenges and Future Directions

Despite the breakthrough, challenges remain before biosynthesized psilocybin becomes widely used in therapy. Regulatory hurdles are significant. Psilocybin remains a Schedule I controlled substance in the United States, creating legal and bureaucratic obstacles for researchers and manufacturers. However, attitudes are shifting, with several cities and states decriminalizing psilocybin or creating frameworks for its therapeutic use. Scaling up production from laboratory to industrial levels presents technical challenges. What works in a small fermenter doesn't always translate directly to large-scale production. The research team is already working on next steps. "We're looking at further optimizing the pathway, improving the efficiency of the bacterial host, and developing more sustainable production methods," says Jones. "There's still room for improvement. "They're also exploring ways to reduce production costs even further and developing methods to ensure the purity and consistency of the final product—essential requirements for pharmaceutical applications.

A New Era for Mental Health Treatment?

As research on psychedelic therapy accelerates, innovations like this biosynthesis breakthrough could help usher in a new paradigm in mental health treatment—one where previously treatment-resistant conditions have new options for relief. "We're at an exciting intersection of ancient wisdom and cutting-edge biotechnology," reflects Dr. Grace Kemmerly, another researcher involved in the study. "These compounds have been used for healing for thousands of years. Now we're finding ways to produce them that combine the best of traditional knowledge with modern science. "For the millions of people struggling with conditions like treatment-resistant depression, PTSD, and addiction, this research represents more than just an interesting scientific achievement—it represents hope for new treatment options that might succeed where others have failed. As clinical trials continue and production methods improve, we may be witnessing the early stages of a transformation in mental health care—one tiny bacterial cell at a time.

Disclaimer: Psychedelic Assisted Psychotherapy has not been approved by any regulatory agencies in the United States, and the safety and efficacy are still not formally established at the time of this writing. 

References

Keller, M. R., McKinney, M. G., Sen, A. K., Guagliardo, F. G., Hellwarth, E. B., Islam, K. N., Kaplan, N. A., Gibbons Jr., W. J., Kemmerly, G. E., Meers, C., Wang, X., & Jones, J. A. (2025). Psilocybin biosynthesis enhancement through gene source optimization. Metabolic Engineering, 91, 119-129. https://doi.org/10.1016/j.ymben.2025.04.003

Adams, A. M., Kaplan, N. A., Wei, Z., Brinton, J. D., Monnier, C. S., Enacopol, A. L., Ramelot, T. A., & Jones, J. A. (2019). In vivo production of psilocybin in E. coli. Metabolic Engineering, 56, 111-119.  https://doi.org/10.1016/j.ymben.2019.09.009

Fricke, J., Blei, F., & Hoffmeister, D. (2017). Enzymatic synthesis of psilocybin. Angewandte Chemie International Edition, 56(40), 12352-12355.  https://doi.org/10.1002/anie.201705489

Hoefgen, S., Lin, J., Fricke, J., Stroe, M. C., Mattern, D. J., Kufs, J. E., Hortschansky, P., Brakhage, A. A., Hoffmeister, D., & Valiante, V. (2018). Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi. Metabolic Engineering, 48, 44-51.  https://doi.org/10.1016/j.ymben.2018.05.014

Milne, N., Thomsen, P., Mølgaard Knudsen, N., Rubaszka, P., Kristensen, M., & Borodina, I. (2020). Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives. Metabolic Engineering, 60, 25-36.   https://doi.org/10.1016/j.ymben.2019.12.007